NANBH
MCID: HPT001
MIFTS: 68

Hepatitis C (NANBH) malady

Categories: Skin diseases, Infectious diseases, Liver diseases, Genetic diseases, Rare diseases, Gastrointestinal diseases, Immune diseases

Aliases & Classifications for Hepatitis C

Aliases & Descriptions for Hepatitis C:

Name: Hepatitis C 12 52 41 42 14 69
Hepatitis C, Chronic 42 69
Chronic Hepatitis C 12 14
Hepatitis C Infection 12
Hepatitis Nona Nonb 12
Hepatitis C Chronic 52
Viral Hepatitis C 12
Nanbh 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1883
ICD10 33 B19.2 B19.20
ICD9CM 35 070.7
NCIt 47 C3098
UMLS 69 C0019196

Summaries for Hepatitis C

MedlinePlus : 41 your liver is the largest organ inside your body. it helps your body digest food, store energy, and remove poisons. hepatitis is an inflammation of the liver. one type, hepatitis c, is caused by the hepatitis c virus (hcv). it usually spreads through contact with infected blood. it can also spread through sex with an infected person and from mother to baby during childbirth. most people who are infected with hepatitis c don't have any symptoms for years. if you do get symptoms, you may feel as if you have the flu. you may also have jaundice, a yellowing of skin and eyes, dark-colored urine, and pale bowel movements. a blood test can tell if you have it. usually, hepatitis c does not get better by itself. the infection can last a lifetime and may lead to cirrhosis (scarring of the liver) or liver cancer. medicines sometimes help, but side effects can be a problem. serious cases may need a liver transplant. there is no vaccine for hcv. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Hepatitis C, also known as hepatitis c, chronic, is related to hepatitis c virus and erysipelas, and has symptoms including fever, fatigue and loss of appetite. An important gene associated with Hepatitis C is SCARB1 (Scavenger Receptor Class B Member 1), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Cyclosporine and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and kidney, and related phenotypes are Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and hematopoietic system

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in liver, has material basis in Hepatitis C virus, which is transmitted_by blood from an infected person enters the body of an uninfected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 71 Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the... more...

Related Diseases for Hepatitis C

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis C via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 469)
id Related Disease Score Top Affiliating Genes
1 hepatitis c virus 33.7 CLEC4M DDX58 IFNA1 IRF3 TLR3
2 erysipelas 29.4 IFNA1 RAF1
3 hemoglobinopathy 29.3 IFNA1 IFNA2 IFNB1
4 severe acute respiratory syndrome 29.3 DDX58 IFNA1 IFNB1 IRF3 IRF7
5 hereditary hemorrhagic telangiectasia 28.4 CD81 CLDN1 DDX58 EIF2AK2 GPT IFNA1
6 chronic end-stage hepatitis c 11.9
7 recurrent hepatitis c virus induced liver disease in liver transplant recipients 11.9
8 hepatitis 11.7
9 hepatocellular carcinoma 11.4
10 cryoglobulinemia 11.3
11 liver disease 11.2
12 porphyria cutanea tarda 11.2
13 fatty liver disease 11.1
14 linear lichen planus 11.1
15 fibrillary glomerulonephritis 11.1
16 immunotactoid glomerulopathy 11.1
17 ifnl3-related altered drug metabolism 10.9
18 immunotactoid or fibrillary glomerulopathy 10.8
19 papular mucinosis 10.8
20 capillariasis 10.8
21 pars planitis 10.8
22 intermediate uveitis 10.8
23 hepatitis b 10.4
24 glomerulonephritis 10.3
25 benign exophthalmos syndrome 10.3 IFNA1 IFNB1
26 viral hepatitis 10.3
27 lymphoma 10.3
28 xeroderma pigmentosum, group a 10.3 EIF2AK2 IFNA1 STAT1
29 porphyria 10.3
30 malignant glioma 10.3 IFNA1 IFNA2
31 spermatocytoma 10.3 CD81 IRF3 IRF7
32 central nervous system angiosarcoma 10.3 DDX58 IFNA1 IRF7
33 methylmalonic aciduria and homocystinuria, cblj type 10.3 IFNA1 IFNB1 STAT1
34 noninfectious dermatoses of eyelid 10.2 GPT IFNA1 IFNA2
35 membranoproliferative glomerulonephritis 10.2
36 osmotic diarrhea 10.2 DDX58 IFNB1 IRF3
37 ceruminoma 10.2 IFNA1 IFNA2
38 thyroiditis 10.2
39 senile cataract 10.2 DDX58 EIF2AK2 IFNA1 IFNA2 LDLR
40 esophagus leiomyoma 10.2 IFNB1 IRF7 STAT1
41 liver cirrhosis 10.2
42 vasculitis 10.2
43 turner syndrome 10.2 IFNAR1 IFNB1 IRF3
44 lichen planus 10.2
45 hereditary spastic paraplegia 10.2 GPT IFNA1 IFNA2 TLR3
46 trachoma 10.2 IRF3 STAT1 TLR3
47 plantar fasciitis 10.2 CLEC4M DDX58 IRF3 TLR3
48 embryonal carcinoma 10.2 EIF2AK2 IFNA1 IFNB1 IRF3 IRF7
49 hyperimmunoglobulin syndrome 10.1 CLEC4M IFNA1 IFNB1 IRF3 STAT1
50 erythrocytosis, somatic 10.1 IFNA1 IFNA2 JAK1

Graphical network of the top 20 diseases related to Hepatitis C:



Diseases related to Hepatitis C

Symptoms & Phenotypes for Hepatitis C

Symptoms:

12
  • fever
  • fatigue
  • loss of appetite
  • nausea
  • vomiting
  • abdominal pain
  • clay-colored bowel movements
  • joint pain
  • jaundice

GenomeRNAi Phenotypes related to Hepatitis C according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 9.1 CD81 CLDN1 GPT IRF3 IRF7 RAF1

MGI Mouse Phenotypes related to Hepatitis C:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.2 LDLR RAF1 SCARB1 STAT1 TLR3 CD81
2 homeostasis/metabolism MP:0005376 10.13 IRF7 JAK1 LDLR RAF1 SCARB1 STAT1
3 immune system MP:0005387 10.03 CD81 CLEC4M DDX58 EIF2AK2 IFNAR1 IFNAR2
4 mortality/aging MP:0010768 9.77 CLDN1 CLEC4M DDX58 EIF2AK2 IFNAR1 IFNAR2
5 neoplasm MP:0002006 9.23 DDX58 EIF2AK2 IFNAR1 IFNAR2 IFNB1 RAF1

Drugs & Therapeutics for Hepatitis C

Drugs for Hepatitis C (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 642)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
3
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
4
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
5
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
6
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
7
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
8
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
9
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1 99210-65-8, 215647-85-1
10
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
11
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
12
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
13
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
14
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
15
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
16
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
17
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
18
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
19
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Phase 3 6493-05-6 4740
20
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
21
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
22
Insulin Glargine Approved Phase 4 160337-95-1
23
Insulin-glulisine Approved Phase 4 207748-29-6
24
Zinc Approved Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
25
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
26
Isoniazid Approved Phase 4,Phase 2,Phase 3 54-85-3 3767
27
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
28
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2 3424-98-4 159269
29
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
30
Pyrazinamide Approved Phase 4 98-96-4 1046
31
Rifampin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
32
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1 923604-59-5 66576988
33
Sofosbuvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1190307-88-0 45375808
34
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1 1256388-51-8 67505836
35
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
36
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
37
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154598-52-4 64139
38
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1 30516-87-1 35370
39
Interferon alfacon-1 Approved Phase 4,Phase 3,Phase 2 118390-30-0 9554198
40
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 376348-65-1 3002977
41
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 52485-79-7 40400 644073
42
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 192725-17-0 92727
43
Lenograstim Approved Phase 4,Phase 3,Phase 1,Phase 2 135968-09-1
44
Nevirapine Approved Phase 4,Phase 2,Phase 3 129618-40-2 4463
45
Rifaximin Approved, Investigational Phase 4,Phase 2 80621-81-4 6436173
46
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
47
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
48
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
49
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
50
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show top 50) (show all 2450)
id Name Status NCT ID Phase
1 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4
2 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4
3 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4
4 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
5 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4
6 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4
7 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4
8 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4
9 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4
10 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4
11 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4
12 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
13 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4
14 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4
15 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4
16 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4
17 Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. Unknown status NCT00179413 Phase 4
18 Ribavirin, Its Dosing Regime Unknown status NCT00484328 Phase 4
19 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4
20 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4
21 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4
22 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8 Unknown status NCT01683786 Phase 4
23 Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients Unknown status NCT00526448 Phase 4
24 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
25 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4
26 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
27 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4
28 Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat (Vitagel) Unknown status NCT01230931 Phase 4
29 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
30 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4
31 NAT2 in Re-challenge of INH in Patients With Hepatitis Unknown status NCT00728546 Phase 4
32 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4
33 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Unknown status NCT01968395 Phase 4
34 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4
35 Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation Completed NCT00821587 Phase 4
36 Australian Trial in Acute Hepatitis C Completed NCT00192569 Phase 4
37 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4
38 The SIM-SOF Trial for Hepatitis C Completed NCT02168361 Phase 4
39 Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) Completed NCT02768961 Phase 4
40 Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C Completed NCT00917358 Phase 4
41 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Completed NCT00938860 Phase 4
42 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4
43 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4
44 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4
45 Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients Completed NCT00132210 Phase 4
46 Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients Completed NCT01469884 Phase 4
47 PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. Completed NCT00087633 Phase 4
48 A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C Completed NCT01675427 Phase 4
49 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4
50 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4

Search NIH Clinical Center for Hepatitis C

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: hepatitis c

Genetic Tests for Hepatitis C

Anatomical Context for Hepatitis C

MalaCards organs/tissues related to Hepatitis C:

39
Liver, T Cells, Kidney, Testes, Skin, B Cells, Thyroid

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis C:

18
Liver

Publications for Hepatitis C

Articles related to Hepatitis C:

(show top 50) (show all 6542)
id Title Authors Year
1
Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis. ( 27666584 )
2017
2
Changes in the Prevalence of Hepatitis C Virus Infection, Non-alcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. ( 28088461 )
2017
3
A preliminary investigation on single nucleotide polymorphism rs2287622 of bile salt export pump gene in patients with chronic hepatitis C virus infection in Hunan, China. ( 28292275 )
2017
4
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. ( 28535298 )
2017
5
Direct-acting antivirals for hepatitis C virus induce a rapid clinical and biochemical remission of porphyria cutanea tarda. ( 28369802 )
2017
6
Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations. ( 28512229 )
2017
7
A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naA^ve chronic hepatitis C patients in Taiwan. ( 28088273 )
2017
8
Hepatitis C virus lipoviroparticles (HCV-LVP) assemble in the endoplasmic reticulum (ER) and bud off from the ER to Golgi in COPII vesicles. ( 28515296 )
2017
9
Interleukin 10 gene single nucleotide polymorphisms in Polish patients with chronic hepatitis C: Analysis of association with severity of disease and treatment outcome. ( 27793650 )
2017
10
Single nucleotide polymorphisms of interleukins associated with hepatitis C virus infection in Egypt. ( 28368861 )
2017
11
Clinical development of hepatitis C virus host-targeting agents. ( 28087068 )
2017
12
Genome-wide Association Study Identifies Risk Variants for Lichen Planus in Patients With Hepatitis C Virus Infection. ( 28065765 )
2017
13
Overall Structural Model of NS5A Protein from Hepatitis C Virus and Modulation by Mutations Confering Resistance of Virus Replication to Cyclosporin A. ( 28535337 )
2017
14
JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection. ( 28527663 )
2017
15
The second-generation of highly potent hepatitis C virus (HCV) NS3/4A protease inhibitors: Evolutionary design based on tailor-made amino acids, synthesis and major features of bio-activity. ( 28530544 )
2017
16
Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents. ( 28529212 )
2017
17
Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults. ( 28081037 )
2017
18
Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments. ( 28512226 )
2017
19
A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection. ( 28092171 )
2017
20
Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B. ( 28075394 )
2017
21
Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. ( 28214926 )
2017
22
Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature. ( 28529936 )
2017
23
Hepatitis C virus triggers Golgi fragmentation and autophagy through the immunity-related GTPase M. ( 28389568 )
2017
24
UGT1A1*28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients: Outcomes from a case-control study. ( 28296739 )
2017
25
Development of proteinuria and focal segmental glomerulosclerosis during direct acting antiviral therapy for hepatitis C virus infection (HEP-16-2474.R1). ( 28211090 )
2017
26
Prevalence of relevant NS5A resistance-associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain. ( 28521955 )
2017
27
Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection. ( 28127569 )
2017
28
Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir. ( 28089092 )
2017
29
The impact of chronic hepatitis C infection on cholesterol metabolism in PBMCs is associated with microRNA-146a expression. ( 27888401 )
2017
30
Retinoid BMS411 (4-{[(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl) carbonyl] amino} benzoic acid), a potential inhibitor of NS5A protein of hepatitis C virus, a candidate for combined therapy of hepatitis C infection. ( 28523927 )
2017
31
Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis. ( 28514954 )
2017
32
High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease. ( 28532708 )
2017
33
Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus. ( 28530647 )
2017
34
Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. ( 28516201 )
2017
35
Spontaneous clearance of chronic hepatitis C virus infection in HIV-positive patients, southeastern France. ( 28526244 )
2017
36
Hepatitis C virus alters metabolism of biogenic polyamines by affecting expression of key enzymes of their metabolism. ( 28082202 )
2017
37
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. ( 28521211 )
2017
38
Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant. ( 28083718 )
2017
39
Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. ( 28533673 )
2017
40
Five Near full-length Hepatitis C virus sequences were isolated from HIV coinfected IDUs of China. ( 28075146 )
2017
41
Highly Successful Hepatitis C Virus (HCV) Treatment Outcomes in Human Immunodeficiency Virus/HCV-Coinfected Patients at a Large, Urban, Ryan White Clinic. ( 28534036 )
2017
42
Fatal Relapse of Myelodysplastic Syndrome in a Patient with HIV/Hepatitis C Coinfection Treated with Simeprevir/Sofosbuvir. ( 28088870 )
2017
43
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. ( 28087069 )
2017
44
Evaluation of hepatitis C, hepatitis B, and HIV virus Serology pandemic in thalassemia patients of Shahid Mohammadi Hospital of Bandar Abbas, Iran. ( 28461879 )
2017
45
Immune modulation by the Hepatitis C virus core protein. ( 28092420 )
2017
46
Genotype 3 Infection: The Last Stand of Hepatitis C Virus. ( 28074358 )
2017
47
The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data. ( 28092642 )
2017
48
Exosome mediated intercellular communication between hepatitis C virus infected hepatocytes and hepatic stellate cells. ( 28077652 )
2017
49
ADVANCES WITH USING CRISPR/CAS-MEDIATED GENE EDITING TO TREAT INFECTIONS WITH HEPATITIS B VIRUS AND HEPATITIS C VIRUS. ( 28087399 )
2017
50
Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia. ( 28088084 )
2017

Variations for Hepatitis C

Expression for Hepatitis C

Search GEO for disease gene expression data for Hepatitis C.

Pathways for Hepatitis C

Pathways related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 40)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 CD81 DDX58 EIF2AK2 IFNA1 IFNA2 IFNAR1
2
Show member pathways
13.51 EIF2AK2 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1
3
Show member pathways
13.37 DDX58 EIF2AK2 IFNA1 IFNA2 IFNAR1 IFNAR2
4
Show member pathways
13.28 IFNA1 IFNA2 IFNB1 IRF3 IRF7 JAK1
5
Show member pathways
13.03 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IRF3
6
Show member pathways
12.92 DDX58 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1
7
Show member pathways
12.72 DDX58 IFNA1 IFNA2 IFNB1 IRF3 IRF7
8 12.63 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 JAK1
9 12.58 DDX58 IFNA1 IRF3 IRF7 JAK1 STAT1
10
Show member pathways
12.53 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 RAF1
11
Show member pathways
12.49 DDX58 EIF2AK2 IFNA1 IFNA2 IFNAR1 IFNAR2
12
Show member pathways
12.49 CLEC4M DDX58 EIF2AK2 IFNA1 IFNA2 IFNAR1
13
Show member pathways
12.39 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 JAK1
14
Show member pathways
12.38 DDX58 IRF3 IRF7 TLR3
15 12.29 CLEC4M IFNA1 IFNA2 IFNB1 JAK1 RAF1
16
Show member pathways
12.27 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 JAK1
17 12.26 DDX58 EIF2AK2 IRF3 JAK1
18 12.25 EIF2AK2 IRF3 IRF7 JAK1
19
Show member pathways
12.23 IRF3 JAK1 STAT1 TLR3
20
Show member pathways
12.22 JAK1 LDLR RAF1 STAT1
21
Show member pathways
12.22 IFNB1 IRF3 IRF7 TLR3
22 12.2 CD81 CLDN1 DDX58 EIF2AK2 IFNA1 IFNA2
23 12.18 IFNA1 IFNA2 IFNB1 IRF3 IRF7
24
Show member pathways
12.18 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 IRF3
25 12.06 IFNAR1 IFNAR2 IFNB1 JAK1 STAT1
26
Show member pathways
11.89 JAK1 STAT1 TLR3
27 11.88 IFNB1 IRF7 RAF1
28
Show member pathways
11.86 JAK1 STAT1 TLR3
29 11.79 JAK1 RAF1 STAT1
30 11.77 IFNA1 IFNA2 IFNAR1 IFNAR2 IFNB1 JAK1
31 11.66 JAK1 RAF1 STAT1
32 11.61 IFNAR1 IFNAR2 JAK1 STAT1
33
Show member pathways
11.6 IFNAR1 IFNAR2 RAF1
34 11.48 EIF2AK2 IFNA2 IFNB1 JAK1 STAT1
35 11.45 JAK1 RAF1 STAT1
36 11.42 IFNA1 IFNA2 IFNB1
37
Show member pathways
11.41 EIF2AK2 JAK1 STAT1
38
Show member pathways
11.37 IFNL4 JAK1 STAT1
39 10.88 IFNAR1 IFNB1
40
Show member pathways
10.64 DDX58 EIF2AK2 IFNA2 IFNAR1 IFNAR2 IRF3

GO Terms for Hepatitis C

Cellular components related to Hepatitis C according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.23 CD81 CLDN1 CLEC4M IFNAR1 IFNAR2 LDLR
2 endolysosome membrane GO:0036020 8.96 LDLR TLR3

Biological processes related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 42)
id Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.98 CD81 IFNA2 IFNAR2 IFNB1
2 response to virus GO:0009615 9.95 DDX58 EIF2AK2 IFNAR1 IFNAR2 IFNB1 IRF7
3 defense response GO:0006952 9.92 IFNA1 IFNA2 IFNB1 TLR3
4 viral entry into host cell GO:0046718 9.88 CD81 CLDN1 CLEC4M LDLR SCARB1
5 interferon-gamma-mediated signaling pathway GO:0060333 9.84 IRF3 IRF7 JAK1 STAT1
6 B cell differentiation GO:0030183 9.83 IFNA1 IFNA2 IFNB1
7 positive regulation of interferon-beta production GO:0032728 9.83 DDX58 IFNAR1 IRF3 IRF7 TLR3
8 humoral immune response GO:0006959 9.82 IFNA1 IFNA2 IFNB1
9 positive regulation of type I interferon production GO:0032481 9.81 IRF3 IRF7 TLR3
10 B cell proliferation GO:0042100 9.79 IFNA1 IFNA2 IFNB1
11 JAK-STAT cascade GO:0007259 9.78 IFNAR1 IFNAR2 STAT1
12 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.77 IRF3 IRF7 TLR3
13 T cell activation involved in immune response GO:0002286 9.74 IFNA1 IFNA2 IFNB1
14 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.73 IFNA1